MicroRNAs and growth factors: An alliance propelling tumor progression

Journal of Clinical Medicine

Volumn 4, Issue 8, 2015, Pages 1578-1599

  Kedmi, Merav ^a,b   Sas Chen, Aldema ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cancer therapy; Carcinoma; Epidermal growth factor (EGF); Metastasis; Network; Receptor tyrosine kinase; Signal transduction; Transcription

Indexed keywords

BONE MORPHOGENETIC PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; MICRORNA; MIRAVIRSEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA;

BIOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DOWN REGULATION; HUMAN; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 85048838733     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4081578     Document Type: Review

References (125)

1. Solomon, E.; Borrow, J.; Goddard, A.D. Chromosome aberrations and cancer. Science 1991, 254, 1153-1160.
2. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
3. Tomasetti, C.; Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015, 347, 78-81.
4. Chaffer, C.L.; Weinberg, R.A. How does multistep tumorigenesis really proceed? Cancer Discov. 2015, 5, 22-24.
5. Beerenwinkel, N.; Antal, T.; Dingli, D.; Traulsen, A.; Kinzler, K.W.; Velculescu, V.E.; Vogelstein, B.; Nowak, M.A. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 2007, 3, e225.
6. Witsch, E.; Sela, M.; Yarden, Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 2010, 25, 85-101.
7. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4, 177-183.
8. Sporn, M.B.; Todaro, G.J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 1980, 303, 878-880.
9. Greco, A.; Fusetti, L.; Villa, R.; Sozzi, G.; Minoletti, F.; Mauri, P.; Pierotti, M.A. Transforming activity of the chimeric sequence formed by the fusion of collagen gene col1a1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 1998, 17, 1313-1319.
10. Shimizu, A.; O'Brien, K.P.; Sjoblom, T.; Pietras, K.; Buchdunger, E.; Collins, V.P.; Heldin, C.H.; Dumanski, J.P.; Ostman, A. The dermatofibrosarcoma protuberans-associated collagen type ialpha1/platelet-derived growth factor (pdgf) b-chain fusion gene generates a transforming protein that is processed to functional pdgf-bb. Cancer Res. 1999, 59, 3719-3723.
11. Hynes, N.E.; Watson, C.J. Mammary gland growth factors: Roles in normal development and in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2, a003186.
12. Kovacs, E.; Zorn, J.A.; Huang, Y.; Barros, T.; Kuriyan, J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu. Rev. Biochem. 2015, 84, 739-764.
13. Tarcic, G.; Avraham, R.; Pines, G.; Amit, I.; Shay, T.; Lu, Y.; Zwang, Y.; Katz, M.; Ben-Chetrit, N.; Jacob-Hirsch, J.; et al. Egr1 and the erk-erf axis drive mammary cell migration in response to egf. FASEB J. 2012, 26, 1582-1592.
14. Huang, H.; Tindall, D.J. Dynamic foxo transcription factors. J. Cell Sci. 2007, 120, 2479-2487.
15. Amit, I.; Citri, A.; Shay, T.; Lu, Y.; Katz, M.; Zhang, F.; Tarcic, G.; Siwak, D.; Lahad, J.; Jacob-Hirsch, J.; et al. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 2007, 39, 503-512.
16. Tullai, J.W.; Schaffer, M.E.; Mullenbrock, S.; Sholder, G.; Kasif, S.; Cooper, G.M. Immediateearly and delayed primary response genes are distinct in function and genomic architecture. J. Biol. Chem. 2007, 282, 23981-23995.
17. Avraham, R.; Yarden, Y. Feedback regulation of egfr signalling: Decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12, 104-117.
18. Han, J.; Lee, Y.; Yeom, K.H.; Kim, Y.K.; Jin, H.; Kim, V.N. The drosha-dgcr8 complex in primary microrna processing. Genes Dev. 2004, 18, 3016-3027.
19. Grishok, A.; Pasquinelli, A.E.; Conte, D.; Li, N.; Parrish, S.; Ha, I.; Baillie, D.L.; Fire, A.; Ruvkun, G.; Mello, C.C. Genes and mechanisms related to rna interference regulate expression of the small temporal rnas that control c. Elegans developmental timing. Cell 2001, 106, 23-34.
20. Song, J.J.; Smith, S.K.; Hannon, G.J.; Joshua-Tor, L. Crystal structure of argonaute and its implications for risc slicer activity. Science 2004, 305, 1434-1437.
21. Chendrimada, T.P.; Finn, K.J.; Ji, X.; Baillat, D.; Gregory, R.I.; Liebhaber, S.A.; Pasquinelli, A.E.; Shiekhattar, R. Microrna silencing through risc recruitment of eif6. Nature 2007, 447, 823-828.
22. Tijsterman, M.; Plasterk, R.H. Dicers at risc; the mechanism of rnai. Cell 2004, 117, 1-3.
23. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell 2005, 120, 15-20.
24. Zamore, P.D.; Haley, B. Ribo-gnome: The big world of small rnas. Science 2005, 309, 1519-1524.
25. Baek, D.; Villen, J.; Shin, C.; Camargo, F.D.; Gygi, S.P.; Bartel, D.P. The impact of micrornas on protein output. Nature 2008, 455, 64-71.
26. Croce, C.M.; Calin, G.A. Mirnas, cancer, and stem cell division. Cell 2005, 122, 6-7.
27. Lin, S.; Gregory, R.I. Microrna biogenesis pathways in cancer. Nat. Rev. Cancer 2015, 15, 321-333.
28. Hata, A.; Lieberman, J. Dysregulation of microrna biogenesis and gene silencing in cancer. Sci. Signal. 2015, 8, re3.
29. Avery-Kiejda, K.A.; Braye, S.G.; Forbes, J.F.; Scott, R.J. The expression of dicer and drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer. BMC Cancer 2014, 14, 253.
30. Poursadegh Zonouzi, A.A.; Nejatizadeh, A.; Rahmati-Yamchi, M.; Fardmanesh, H.; Shakerizadeh, S.; Poursadegh Zonouzi, A.; Nejati-Koshki, K.; Shekari, M. Dysregulated expression of dicer in invasive ductal breast carcinoma. Med. Oncol. 2015, 32, 643.
31. Vincenzi, B.; Iuliani, M.; Zoccoli, A.; Pantano, F.; Fioramonti, M.; de Lisi, D.; Frezza, A.M.; Rabitti, C.; Perrone, G.; Onetti Muda, A.; et al. Deregulation of dicer and mir-155 expression in liposarcoma. Oncotarget 2015, 6, 10586-10591.
32. Shen, J.; Xia, W.; Khotskaya, Y.B.; Huo, L.; Nakanishi, K.; Lim, S.O.; Du, Y.; Wang, Y.; Chang, W.C.; Chen, C.H.; et al. Egfr modulates microrna maturation in response to hypoxia through phosphorylation of ago2. Nature 2013, 497, 383-387.
33. Davis, B.N.; Hilyard, A.C.; Lagna, G.; Hata, A. Smad proteins control drosha-mediated microrna maturation. Nature 2008, 454, 56-61.
34. Avraham, R.; Sas-Chen, A.; Manor, O.; Steinfeld, I.; Shalgi, R.; Tarcic, G.; Bossel, N.; Zeisel, A.; Amit, I.; Zwang, Y.; et al. Egf decreases the abundance of micrornas that restrain oncogenic transcription factors. Sci. Signal. 2010, 3, ra43.
35. Kedmi, M.; Ben-Chetrit, N.; Korner, C.; Mancini, M.; Ben-Moshe, N.B.; Lauriola, M.; Lavi, S.; Biagioni, F.; Carvalho, S.; Cohen-Dvashi, H.; et al. Egf induces micrornas that target suppressors of cell migration: Mir-15b targets mtss1 in breast cancer. Sci. Signal. 2015, 8, ra29.
36. Katz, M.; Amit, I.; Citri, A.; Shay, T.; Carvalho, S.; Lavi, S.; Milanezi, F.; Lyass, L.; Amariglio, N.; Jacob-Hirsch, J.; et al. A reciprocal tensin-3-cten switch mediates egf-driven mammary cell migration. Nat. Cell Biol. 2007, 9, 961-969.
37. Llorens, F.; Hummel, M.; Pantano, L.; Pastor, X.; Vivancos, A.; Castillo, E.; Mattlin, H.; Ferrer, A.; Ingham, M.; Noguera, M.; et al. Microarray and deep sequencing cross-platform analysis of the mirrnome and isomir variation in response to epidermal growth factor. BMC Genomics 2013, 14, 371.
38. Lu, W.C.; Kao, S.Y.; Yang, C.C.; Tu, H.F.; Wu, C.H.; Chang, K.W.; Lin, S.C. Egf up-regulates mir-31 through the c/ebpbeta signal cascade in oral carcinoma. PLoS ONE 2014, 9, e108049.
39. Ben-Chetrit, N.; Chetrit, D.; Russell, R.; Korner, C.; Mancini, M.; Abdul-Hai, A.; Itkin, T.; Carvalho, S.; Cohen-Dvashi, H.; Koestler, W.J.; et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci. Signal. 2015, 8, ra7.
40. Alanazi, I.; Hoffmann, P.; Adelson, D.L. Micrornas are part of the regulatory network that controls egf induced apoptosis, including elements of the jak/stat pathway, in a431 cells. PLoS ONE 2015, 10, e0120337.
41. Gomez, G.G.; Volinia, S.; Croce, C.M.; Zanca, C.; Li, M.; Emnett, R.; Gutmann, D.H.; Brennan, C.W.; Furnari, F.B.; Cavenee, W.K. Suppression of microrna-9 by mutant egfr signaling upregulates foxp1 to enhance glioblastoma tumorigenicity. Cancer Res. 2014, 74, 1429-1439.
42. Kao, C.J.; Martiniez, A.; Shi, X.B.; Yang, J.; Evans, C.P.; Dobi, A.; deVere White, R.W.; Kung, H.J. Mir-30 as a tumor suppressor connects egf/src signal to erg and emt. Oncogene 2014, 33, 2495-2503.
43. Kefas, B.; Godlewski, J.; Comeau, L.; Li, Y.; Abounader, R.; Hawkinson, M.; Lee, J.; Fine, H.; Chiocca, E.A.; Lawler, S.; et al. Microrna-7 inhibits the epidermal growth factor receptor and the akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68, 3566-3572.
44. Webster, R.J.; Giles, K.M.; Price, K.J.; Zhang, P.M.; Mattick, J.S.; Leedman, P.J. Regulation of epidermal growth factor receptor signaling in human cancer cells by microrna-7. J. Biol. Chem. 2009, 284, 5731-5741.
45. Weiss, G.J.; Bemis, L.T.; Nakajima, E.; Sugita, M.; Birks, D.K.; Robinson, W.A.; Varella-Garcia, M.; Bunn, P.A., Jr.; Haney, J.; Helfrich, B.A.; et al. Egfr regulation by microrna in lung cancer: Correlation with clinical response and survival to gefitinib and egfr expression in cell lines. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2008, 19, 1053-1059.
46. Chiyomaru, T.; Seki, N.; Inoguchi, S.; Ishihara, T.; Mataki, H.; Matsushita, R.; Goto, Y.; Nishikawa, R.; Tatarano, S.; Itesako, T.; et al. Dual regulation of receptor tyrosine kinase genes egfr and c-met by the tumor-suppressive microrna-23b/27b cluster in bladder cancer. Int. J. Oncol. 2015, 46, 487-496.
47. Wang, L.K.; Hsiao, T.H.; Hong, T.M.; Chen, H.Y.; Kao, S.H.; Wang, W.L.; Yu, S.L.; Lin, C.W.; Yang, P.C. Microrna-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS ONE 2014, 9, e96765.
48. Cui, W.; Zhang, S.; Shan, C.; Zhou, L.; Zhou, Z. Microrna-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the egfr/akt signaling pathway. FEBS J. 2013, 280, 3962-3974.
49. Liu, L.; Shao, X.; Gao, W.; Zhang, Z.; Liu, P.; Wang, R.; Huang, P.; Yin, Y.; Shu, Y. Microrna-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 2012, 279, 3800-3812.
50. Kumaraswamy, E.; Wendt, K.L.; Augustine, L.A.; Stecklein, S.R.; Sibala, E.C.; Li, D.; Gunewardena, S.; Jensen, R.A. Brca1 regulation of epidermal growth factor receptor (egfr) expression in human breast cancer cells involves microrna-146a and is critical for its tumor suppressor function. Oncogene 2014, doi:10.1038/onc.2014.363.
51. Katakowski, M.; Zheng, X.; Jiang, F.; Rogers, T.; Szalad, A.; Chopp, M. Mir-146b-5p suppresses egfr expression and reduces in vitro migration and invasion of glioma. Cancer Investig. 2010, 28, 1024-1030.
52. Rao, S.A.; Arimappamagan, A.; Pandey, P.; Santosh, V.; Hegde, A.S.; Chandramouli, B.A.; Somasundaram, K. Mir-219-5p inhibits receptor tyrosine kinase pathway by targeting egfr in glioblastoma. PLoS ONE 2013, 8, e63164.
53. Wang, L.; Yao, J.; Shi, X.; Hu, L.; Li, Z.; Song, T.; Huang, C. Microrna-302b suppresses cell proliferation by targeting egfr in human hepatocellular carcinoma smmc-7721 cells. BMC Cancer 2013, 13, 448.
54. Zhang, Y.; Schiff, D.; Park, D.; Abounader, R. Microrna-608 and microrna-34a regulate chordoma malignancy by targeting egfr, bcl-xl and met. PLoS ONE 2014, 9, e91546.
55. Uhlmann, S.; Mannsperger, H.; Zhang, J.D.; Horvat, E.A.; Schmidt, C.; Kublbeck, M.; Henjes, F.; Ward, A.; Tschulena, U.; Zweig, K.; et al. Global microrna level regulation of egfr-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol. 2012, 8, 570.
56. Pagliuca, A.; Valvo, C.; Fabrizi, E.; di Martino, S.; Biffoni, M.; Runci, D.; Forte, S.; de Maria, R.; Ricci-Vitiani, L. Analysis of the combined action of mir-143 and mir-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2013, 32, 4806-4813.
57. Pekow, J.R.; Dougherty, U.; Mustafi, R.; Zhu, H.; Kocherginsky, M.; Rubin, D.T.; Hanauer, S.B.; Hart, J.; Chang, E.B.; Fichera, A.; et al. Mir-143 and mir-145 are downregulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes. Inflamm. Bowel Dis. 2012, 18, 94-100.
58. Xu, B.; Niu, X.; Zhang, X.; Tao, J.; Wu, D.; Wang, Z.; Li, P.; Zhang, W.; Wu, H.; Feng, N.; et al. Mir-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of kras. Mol. Cell. Biochem. 2011, 350, 207-213.
59. Wu, X.; Bhayani, M.K.; Dodge, C.T.; Nicoloso, M.S.; Chen, Y.; Yan, X.; Adachi, M.; Thomas, L.; Galer, C.E.; Jiffar, T.; et al. Coordinated targeting of the egfr signaling axis by microrna-27a*. Oncotarget 2013, 4, 1388-1398.
60. Leivonen, S.K.; Sahlberg, K.K.; Makela, R.; Due, E.U.; Kallioniemi, O.; Borresen-Dale, A.L.; Perala, M. High-throughput screens identify micrornas essential for her2 positive breast cancer cell growth. Mol. Oncol. 2014, 8, 93-104.
61. Giles, K.M.; Barker, A.; Zhang, P.M.; Epis, M.R.; Leedman, P.J. Microrna regulation of growth factor receptor signaling in human cancer cells. Methods Mol. Biol. 2011, 676, 147-163.
62. Epis, M.R.; Giles, K.M.; Barker, A.; Kendrick, T.S.; Leedman, P.J. Mir-331-3p regulates erbb-2 expression and androgen receptor signaling in prostate cancer. J. Biol. Chem. 2009, 284, 24696-24704.
63. Bischoff, A.; Bayerlova, M.; Strotbek, M.; Schmid, S.; Beissbarth, T.; Olayioye, M.A. A global microrna screen identifies regulators of the erbb receptor signaling network. Cell Commun. Signal. 2015, 13, 5.
64. Scott, G.K.; Goga, A.; Bhaumik, D.; Berger, C.E.; Sullivan, C.S.; Benz, C.C. Coordinate suppression of erbb2 and erbb3 by enforced expression of micro-rna mir-125a or mir-125b. J. Biol. Chem. 2007, 282, 1479-1486.
65. Liang, H.; Liu, M.; Yan, X.; Zhou, Y.; Wang, W.; Wang, X.; Fu, Z.; Wang, N.; Zhang, S.; Wang, Y.; et al. Mir-193a-3p functions as a tumor suppressor in lung cancer by down-regulating erbb4. J. Biol. Chem. 2015, 290, 926-940.
66. Yu, T.; Li, J.; Yan, M.; Liu, L.; Lin, H.; Zhao, F.; Sun, L.; Zhang, Y.; Cui, Y.; Zhang, F.; et al. Microrna-193a-3p and-5p suppress the metastasis of human non-small-cell lung cancer by downregulating the erbb4/pik3r3/mtor/s6k2 signaling pathway. Oncogene 2015, 34, 413-423.
67. Zhang, M.; Yang, Q.; Zhang, L.; Zhou, S.; Ye, W.; Yao, Q.; Li, Z.; Huang, C.; Wen, Q.; Wang, J. Mir-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting erbb4. J. Exp. Clin. Cancer Res. 2014, 33, 10.
68. Cho, W.C.; Chow, A.S.; Au, J.S. Mir-145 inhibits cell proliferation of human lung adenocarcinoma by targeting egfr and nudt1. RNA Biol. 2011, 8, 125-131.
69. Zhu, H.; Dougherty, U.; Robinson, V.; Mustafi, R.; Pekow, J.; Kupfer, S.; Li, Y.C.; Hart, J.; Goss, K.; Fichera, A.; et al. Egfr signals downregulate tumor suppressors mir-143 and mir-145 in western diet-promoted murine colon cancer: Role of g1 regulators. Mol. Cancer Res. 2011, 9, 960-975.
70. Guo, Y.H.; Zhang, C.; Shi, J.; Xu, M.H.; Liu, F.; Yuan, H.H.; Wang, J.Y.; Jiang, B.; Gao, F.H. Abnormal activation of the egfr signaling pathway mediates the downregulation of mir145 through the erk1/2 in non-small cell lung cancer. Oncol. Rep. 2014, 31, 1940-1946.
71. Zhang, K.L.; Han, L.; Chen, L.Y.; Shi, Z.D.; Yang, M.; Ren, Y.; Chen, L.C.; Zhang, J.X.; Pu, P.Y.; Kang, C.S. Blockage of a mir-21/egfr regulatory feedback loop augments anti-egfr therapy in glioblastomas. Cancer Lett. 2014, 342, 139-149.
72. Seike, M.; Goto, A.; Okano, T.; Bowman, E.D.; Schetter, A.J.; Horikawa, I.; Mathe, E.A.; Jen, J.; Yang, P.; Sugimura, H.; et al. Mir-21 is an egfr-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. USA 2009, 106, 12085-12090.
73. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
74. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of micro-rna genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524-15529.
75. Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; et al. A microrna expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257-2261.
76. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. Microrna expression profiles classify human cancers. Nature 2005, 435, 834-838.
77. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; et al. Circulating micrornas as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
78. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; et al. Characterization of micrornas in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997-1006.
79. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y.; et al. Reduced expression of the let-7 micrornas in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64, 3753-3756.
80. Nelson, P.T.; Baldwin, D.A.; Scearce, L.M.; Oberholtzer, J.C.; Tobias, J.W.; Mourelatos, Z. Microarray-based, high-throughput gene expression profiling of micrornas. Nat. Methods 2004, 1, 155-161.
81. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific micrornas from mouse. Curr. Biol.: CB 2002, 12, 735-739.
82. Rosenfeld, N.; Aharonov, R.; Meiri, E.; Rosenwald, S.; Spector, Y.; Zepeniuk, M.; Benjamin, H.; Shabes, N.; Tabak, S.; Levy, A.; et al. Micrornas accurately identify cancer tissue origin. Nat. Biotechnol. 2008, 26, 462-469.
83. Dvinge, H.; Git, A.; Graf, S.; Salmon-Divon, M.; Curtis, C.; Sottoriva, A.; Zhao, Y.; Hirst, M.; Armisen, J.; Miska, E.A.; et al. The shaping and functional consequences of the microrna landscape in breast cancer. Nature 2013, 497, 378-382.
84. Blenkiron, C.; Goldstein, L.D.; Thorne, N.P.; Spiteri, I.; Chin, S.F.; Dunning, M.J.; Barbosa-Morais, N.L.; Teschendorff, A.E.; Green, A.R.; Ellis, I.O.; et al. Microrna expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007, 8, R214.
85. Andorfer, C.A.; Necela, B.M.; Thompson, E.A.; Perez, E.A. Microrna signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med. 2011, 17, 313-319.
86. Enerly, E.; Steinfeld, I.; Kleivi, K.; Leivonen, S.K.; Aure, M.R.; Russnes, H.G.; Ronneberg, J.A.; Johnsen, H.; Navon, R.; Rodland, E.; et al. Mirna-mrna integrated analysis reveals roles for mirnas in primary breast tumors. PLoS ONE 2011, 6, e16915.
87. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T.; et al. Unique microrna molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189-198.
88. Hu, Z.; Chen, X.; Zhao, Y.; Tian, T.; Jin, G.; Shu, Y.; Chen, Y.; Xu, L.; Zen, K.; Zhang, C.; et al. Serum microrna signatures identified in a genome-wide serum microrna expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2010, 28, 1721-1726.
89. Cho, W.C. Micrornas: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42, 1273-1281.
90. Meiri, E.; Mueller, W.C.; Rosenwald, S.; Zepeniuk, M.; Klinke, E.; Edmonston, T.B.; Werner, M.; Lass, U.; Barshack, I.; Feinmesser, M.; et al. A second-generation microrna-based assay for diagnosing tumor tissue origin. Oncologist 2012, 17, 801-812.
91. Nair, V.S.; Maeda, L.S.; Ioannidis, J.P. Clinical outcome prediction by micrornas in human cancer: A systematic review. J. Natl. Cancer Inst. 2012, 104, 528-540.
92. Garzon, R.; Marcucci, G.; Croce, C.M. Targeting micrornas in cancer: Rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9, 775-789.
93. Shibata, C.; Otsuka, M.; Kishikawa, T.; Yoshikawa, T.; Ohno, M.; Takata, A.; Koike, K. Current status of mirna-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol. Cell. Ther. 2013, 1, 5.
94. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of micrornas in vivo with "antagomirs". Nature 2005, 438, 685-689.
95. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H.F.; Berger, U.; et al. Lna-mediated microrna silencing in non-human primates. Nature 2008, 452, 896-899.
96. Xie, J.; Ameres, S.L.; Friedline, R.; Hung, J.H.; Zhang, Y.; Xie, Q.; Zhong, L.; Su, Q.; He, R.; Li, M.; et al. Long-term, efficient inhibition of microrna function in mice using raav vectors. Nat. Methods 2012, 9, 403-409.
97. Cheng, C.J.; Bahal, R.; Babar, I.A.; Pincus, Z.; Barrera, F.; Liu, C.; Svoronos, A.; Braddock, D.T.; Glazer, P.M.; Engelman, D.M.; et al. Microrna silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015, 518, 107-110.
98. Ebert, M.S.; Neilson, J.R.; Sharp, P.A. Microrna sponges: Competitive inhibitors of small rnas in mammalian cells. Nat. Methods 2007, 4, 721-726.
99. Choi, W.Y.; Giraldez, A.J.; Schier, A.F. Target protectors reveal dampening and balancing of nodal agonist and antagonist by mir-430. Science 2007, 318, 271-274.
100. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J. Systemic delivery of tumor suppressor microrna mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther.: J. Am. Soc. Gene Ther. 2011, 19, 1116-1122.
101. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; et al. Therapeutic microrna delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
102. Zeisel, M.B.; Pfeffer, S.; Baumert, T.F. Mir-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J. Hepatol. 2013, 58, 821-823.
103. Jopling, C.L.; Yi, M.; Lancaster, A.M.; Lemon, S.M.; Sarnow, P. Modulation of hepatitis c virus rna abundance by a liver-specific microrna. Science 2005, 309, 1577-1581.
104. Janssen, H.L.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y.; et al. Treatment of hcv infection by targeting microrna. N. Engl. J. Med. 2013, 368, 1685-1694.
105. He, L.; He, X.; Lim, L.P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; et al. A microrna component of the p53 tumour suppressor network. Nature 2007, 447, 1130-1134.
106. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S.; et al. The microrna mir-34a inhibits prostate cancer stem cells and metastasis by directly repressing cd44. Nat. Med. 2011, 17, 211-215.
107. Hu, Q.L.; Jiang, Q.Y.; Jin, X.; Shen, J.; Wang, K.; Li, Y.B.; Xu, F.J.; Tang, G.P.; Li, Z.H. Cationic microrna-delivering nanovectors with bifunctional peptides for efficient treatment of panc-1 xenograft model. Biomaterials 2013, 34, 2265-2276.
108. Reid, G.; Pel, M.E.; Kirschner, M.B.; Cheng, Y.Y.; Mugridge, N.; Weiss, J.; Williams, M.; Wright, C.; Edelman, J.J.; Vallely, M.P.; et al. Restoring expression of mir-16: A novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2013, 24, 3128-3135.
109. Yarden, Y.; Pines, G. The erbb network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12, 553-563.
110. Lovly, C.M.; Shaw, A.T. Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2014, 20, 2249-2256.
111. Donzelli, S.; Mori, F.; Biagioni, F.; Bellissimo, T.; Pulito, C.; Muti, P.; Strano, S.; Blandino, G. Micrornas: Short non-coding players in cancer chemoresistance. Mol. Cell. Ther. 2014, 2, 16.
112. Hummel, R.; Hussey, D.J.; Haier, J. Micrornas: Predictors and modifiers of chemo-and radiotherapy in different tumour types. Eur. J. Cancer 2010, 46, 298-311.
113. MacDonagh, L.; Gray, S.G.; Finn, S.P.; Cuffe, S.; O'Byrne, K.J.; Barr, M.P. The emerging role of micrornas in resistance to lung cancer treatments. Cancer Treat. Rev. 2015, 41, 160-169.
114. Kalinowski, F.C.; Giles, K.M.; Candy, P.A.; Ali, A.; Ganda, C.; Epis, M.R.; Webster, R.J.; Leedman, P.J. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by mir-7. PLoS ONE 2012, 7, e47067.
115. Ye, X.M.; Zhu, H.Y.; Bai, W.D.; Wang, T.; Wang, L.; Chen, Y.; Yang, A.G.; Jia, L.T. Epigenetic silencing of mir-375 induces trastuzumab resistance in her2-positive breast cancer by targeting igf1r. BMC Cancer 2014, 14, 134.
116. Bai, W.D.; Ye, X.M.; Zhang, M.Y.; Zhu, H.Y.; Xi, W.J.; Huang, X.; Zhao, J.; Gu, B.; Zheng, G.X.; Yang, A.G.; et al. Mir-200c suppresses tgf-beta signaling and counteracts trastuzumab resistance and metastasis by targeting znf217 and zeb1 in breast cancer. Int. J. Cancer. J. Int. Cancer 2014, 135, 1356-1368.
117. Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D.; et al. Mir-200 expression regulates epithelial-tomesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15, 5060-5072.
118. Huang, S.; He, R.; Rong, M.; Dang, Y.; Chen, G. Synergistic effect of mir-146a mimic and cetuximab on hepatocellular carcinoma cells. BioMed Res. Int. 2014, 2014, 384121.
119. Zhang, K.L.; Zhou, X.; Han, L.; Chen, L.Y.; Chen, L.C.; Shi, Z.D.; Yang, M.; Ren, Y.; Yang, J.X.; Frank, T.S.; et al. Microrna-566 activates egfr signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Mol. Cancer 2014, 13, 63.
120. Ye, X.; Bai, W.; Zhu, H.; Zhang, X.; Chen, Y.; Wang, L.; Yang, A.; Zhao, J.; Jia, L. Mir-221 promotes trastuzumab-resistance and metastasis in her2-positive breast cancers by targeting pten. BMB Rep. 2014, 47, 268-273.
121. Garofalo, M.; Romano, G.; di Leva, G.; Nuovo, G.; Jeon, Y.J.; Ngankeu, A.; Sun, J.; Lovat, F.; Alder, H.; Condorelli, G.; et al. Egfr and met receptor tyrosine kinase-altered microrna expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 2012, 18, 74-82.
122. Shen, H.; Zhu, F.; Liu, J.; Xu, T.; Pei, D.; Wang, R.; Qian, Y.; Li, Q.; Wang, L.; Shi, Z.; et al. Alteration in mir-21/pten expression modulates gefitinib resistance in non-small cell lung cancer. PLoS ONE 2014, 9, e103305.
123. Gao, Y.; Fan, X.; Li, W.; Ping, W.; Deng, Y.; Fu, X. Mir-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating g protein-coupled receptor 124. Biochem. Biophys. Res. Commun. 2014, 446, 179-186.
124. Zhou, J.Y.; Chen, X.; Zhao, J.; Bao, Z.; Chen, X.; Zhang, P.; Liu, Z.F.; Zhou, J.Y. Microrna-34a overcomes hgf-mediated gefitinib resistance in egfr mutant lung cancer cells partly by targeting met. Cancer Lett. 2014, 351, 265-271.
125. Siu, M.K.; Abou-Kheir, W.; Yin, J.J.; Chang, Y.S.; Barrett, B.; Suau, F.; Casey, O.; Chen, W.Y.; Fang, L.; Hynes, P.; et al. Loss of egfr signaling regulated mir-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget 2014, 5, 3770-3784.